Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$157000.0.

  • Sutro Biopharma's Gains from Investment Securities fell 795000.0% to -$157000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 8652.34%. This contributed to the annual value of $17.5 million for FY2024, which is 291672.03% up from last year.
  • Per Sutro Biopharma's latest filing, its Gains from Investment Securities stood at -$157000.0 for Q3 2025, which was down 795000.0% from -$483000.0 recorded in Q2 2025.
  • Sutro Biopharma's 5-year Gains from Investment Securities high stood at $14.8 million for Q2 2024, and its period low was -$1.1 million during Q4 2023.
  • For the 5-year period, Sutro Biopharma's Gains from Investment Securities averaged around $1.2 million, with its median value being $223362.0 (2021).
  • In the last 5 years, Sutro Biopharma's Gains from Investment Securities skyrocketed by 24640000.0% in 2024 and then crashed by 795000.0% in 2025.
  • Sutro Biopharma's Gains from Investment Securities (Quarter) stood at $1.8 million in 2021, then tumbled by 97.24% to $50000.0 in 2022, then plummeted by 2324.0% to -$1.1 million in 2023, then soared by 311.69% to $2.4 million in 2024, then crashed by 106.67% to -$157000.0 in 2025.
  • Its Gains from Investment Securities was -$157000.0 in Q3 2025, compared to -$483000.0 in Q2 2025 and $180000.0 in Q1 2025.